Lung Cancer Medical Services in China

Lung cancer, a malignant neoplasm originating in the bronchial epithelium or alveolar cells, remains the leading cause of cancer-related mortality worldwide. It is broadly classified into non-small cell lung cancer (NSCLC)—comprising adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—and small cell lung cancer (SCLC), each with distinct histopathological features, molecular profiles, and therapeutic implications. Early-stage disease may be asymptomatic; diagnosis typically relies on low-dose CT screening, PET-CT staging, and tissue confirmation via bronchoscopy or image-guided biopsy. Molecular profiling—including testing for EGFR, ALK, ROS1, BRAF, MET, RET, and PD-L1 expression—is now standard to guide targeted therapy or immunotherapy selection. Treatment modalities span surgical resection (lobectomy or segmentectomy), stereotactic body radiotherapy (SBRT), chemotherapy, precision-targeted agents (e.g., osimertinib, alectinib), and immune checkpoint inhibitors (e.g., pembrolizumab, camrelizumab). Prognosis varies significantly by stage, histology, and biomarker status, underscoring the need for multidisciplinary tumor board evaluation.

China offers compelling advantages for international patients seeking lung cancer care. Its top-tier oncology centers—many accredited by JCI or ISO—house world-class thoracic oncologists trained at institutions including MD Anderson and Memorial Sloan Kettering. Advanced technologies such as robotic-assisted VATS, real-time intraoperative navigation, next-generation sequencing platforms, and domestically developed PD-1 inhibitors (e.g., sintilimab, tislelizumab) are widely deployed. Clinical outcomes align with global benchmarks: five-year survival for Stage I NSCLC exceeds 85% in high-volume centers, and response rates to first-line immunotherapy combinations match or surpass Western data. Crucially, treatment costs in China average 40–60% lower than in the US or Western Europe—without compromising quality—due to streamlined regulatory pathways, domestic biopharma innovation, and efficient hospital operations.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients. We coordinate appointments with certified thoracic oncology specialists, verify hospital credentials, provide itemized, transparent pricing in advance, arrange visa support and accommodation, and assign bilingual case managers for end-to-end clinical and logistical assistance—from pre-travel consultation through post-treatment follow-up.

Treatment Options & Itemized Cost Breakdown: Lung Cancer (Oncology Department)

Non-Surgical / Medical Therapies

*Eligibility*: Confirmed NSCLC or SCLC diagnosis; molecular profiling (EGFR/ALK/ROS1/BRAF/PD-L1) required for targeted/immunotherapy.

• •Targeted Therapy (e.g., Osimertinib, Alect *Criteria*: EGFR-mutated (exon 19 del/L858R) or ALK+ advanced NSCLC

• •Immunotherapy (e.g., Pembrolizumab, Camrelizumab)

• •Chemotherapy (Platinum-doublet: Paclitaxel + Carboplatin)

• •Lobectomy (VATS or robotic-assisted)

• •Sublobar Resection (Wedge/Segmentectomy)

• •SBRT (Stereotactic Body Radiotherapy)

• •Oligometastatic Disease (≤3 mets, lung + adrenal/bone/brain):

• •Malignant Pleural Effusion:

• •Brain Metastases (symptomatic):

• •<65 years, fit, stage IA: VATS lobectomy ($4,200–$6,900) — curative intent, lowest recurrence risk.
• •75+ years, COPD/CHF, stage IB: SBRT ($2,800–$4,300) — avoids surgical morbidity, equivalent local control.
• •Stage IV, EGFR+: Osimertinib ($420/month) + NGS ($280) — superior PFS vs. chemo, outpatient.
• •Budget-constrained, PD-L1 high: Domestic PD-1 inhibitor ($1,100/infusion) — 30–40% lower than imported equivalents.
• •Stage III unresectable: Concurrent chemoradiation** ($5,100–$7,800) — standard of care, includes 30-fraction RT + 2 cycles chemo.